HC Wainwright Expects Reduced Earnings for Legend Biotech

Legend Biotech Co. (NASDAQ:LEGN) – Stock analysts at HC Wainwright lowered their Q4 2025 earnings per share (EPS) estimates for shares of Legend Biotech in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings results on Tuesday, March 11th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.46. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The company had revenue of $186.50 million for the quarter, compared to analysts’ expectations of $179.00 million. During the same period last year, the firm earned ($0.40) EPS. The firm’s revenue for the quarter was up 134.6% on a year-over-year basis.

A number of other brokerages have also recently issued reports on LEGN. Royal Bank of Canada restated an “outperform” rating and issued a $86.00 target price on shares of Legend Biotech in a report on Monday, December 9th. Guggenheim restated a “neutral” rating on shares of Legend Biotech in a report on Wednesday. Piper Sandler restated an “overweight” rating and issued a $78.00 target price on shares of Legend Biotech in a report on Monday, December 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $83.00 target price on shares of Legend Biotech in a report on Monday, December 9th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $79.09.

Legend Biotech Stock Down 2.2 %

Shares of LEGN stock opened at $37.20 on Friday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.98. The stock has a market cap of $6.79 billion, a PE ratio of -39.16 and a beta of 0.19. The business’s fifty day moving average is $35.68 and its 200-day moving average is $40.97. Legend Biotech has a 1 year low of $30.17 and a 1 year high of $69.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in shares of Legend Biotech during the fourth quarter valued at $56,000. Signaturefd LLC boosted its position in Legend Biotech by 1,052.7% during the fourth quarter. Signaturefd LLC now owns 1,729 shares of the company’s stock valued at $56,000 after purchasing an additional 1,579 shares during the last quarter. Shell Asset Management Co. boosted its position in Legend Biotech by 62.0% during the fourth quarter. Shell Asset Management Co. now owns 2,090 shares of the company’s stock valued at $68,000 after purchasing an additional 800 shares during the last quarter. OFI Invest Asset Management acquired a new stake in Legend Biotech during the fourth quarter valued at $77,000. Finally, Quantbot Technologies LP acquired a new stake in Legend Biotech during the third quarter valued at $148,000. Hedge funds and other institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).